Skip to main content
. Author manuscript; available in PMC: 2011 Mar 1.
Published in final edited form as: Gene Ther. 2010 Apr 29;17(9):1162–1174. doi: 10.1038/gt.2010.56

Figure 3. Histopathological findings following subretinal injection with three different rAAV2/5 constructs.

Figure 3

(A1–4) H&E stained retinal section of eyes treated with different titers of rAAV2/5-mOP-GFP: E1048-R (3.27 × 1013 vg/ml) (A1–2); E1048-L (3.27 × 1012 vg/ml) (A3); and P1473-R (3.27 × 1011 vg/ml)) (A4).

(B1–4) H&E stained retinal section of eyes treated with different titers of rAAV2/5-hGRK1-GFP: E1055-R (1.51 × 1013 vg/ml) (B1–2); P1476-L (1.51 × 1012 vg/ml) (B3); and E1055-L (1.51 × 1012 vg/ml) (B4).

(C1–4) H&E stained retinal section of eyes treated with different titers of rAAV2/5-CBA-GFP: E1050-R (4.79 × 1013 vg/ml) (C1); E1050-L (4.79 × 1012 vg/ml) (C2–3); P1475-R (4.79 × 1011 vg/ml) (C4).

Abbreviations: ONL, outer nuclear layer; INL, inner nuclear layer; GCL, ganglion cell layer. Scale bars: (A1, A3, A4, B1, B4, C2) 40 μm; (B3, C4) 20 μm; (C1) 80 μm.